Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany.

Braitsch, Krischan; Schmalbrock, Laura K; Jung, Paul; Bumeder, Irmgard; Kiewe, Philipp; Hecker, Judith S; Verbeek, Mareike; Westermann, Jörg; Bullinger, Lars; Keller, Ulrich; Bassermann, Florian; Krönke, Jan; Götze, Katharina S; Rieger, Kathrin

Braitsch, Krischan; Schmalbrock, Laura K; Jung, Paul; Bumeder, Irmgard; Kiewe, Philipp; Hecker, Judith S; Verbeek, Mareike; Westermann, Jörg; Bullinger, Lars; Keller, Ulrich; Bassermann, Florian; Krönke, Jan; Götze, Katharina S; Rieger, Kathrin.

Afiliación

Braitsch K; Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Schmalbrock LK; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Jung P; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany.
Bumeder I; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Kiewe P; Praxis und Tagesklinik für Hämatologie und internistische Onkologie, Munich, Germany.
Hecker JS; Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany.
Verbeek M; Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Westermann J; Department of Medicine III, Technical University Munich, Klinikum Rechts der Isar, Munich, Germany.
Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Keller U; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany.
Bassermann F; Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Krönke J; German Cancer Consortium (DKTK), Partner Sites Berlin/Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Götze KS; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany.
Rieger K; German Cancer Consortium (DKTK), Partner Sites Berlin/Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Hemasphere ; 6(9): e759, 2022 Sep.

Article en En | MEDLINE | ID: mdl-35966764

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Hemasphere Año: 2022 Tipo del documento: Article País de afiliación: Alemania